ARTICLE

Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study

Tsugumichi Sato1 | Ching-Lan Cheng2,3 | Heung-Woo Park4 | Yea-Huei Kao Yang2 | Min-Suk Yang5 | Mizuki Fujita1 | Yuji Kumagai6 | Masahiro Tohkin7 | Yoshiro Saito8 | Kimie Sai8

1Department of Pharmacy, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan
2School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
3Department of Pharmacy, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
4Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
5Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea
6Clinical Research Center, School of Medicine, Kitasato University, Tokyo, Japan
7Department of Regulatory Science, Graduate School of Pharmaceutical Science, Nagoya City University, Nagoya, Japan
8Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan

Correspondence
Kimie Sai, Division of Medicinal Safety Science, National Institute of Health Sciences, Tonomachi 3-25-26, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan.
Email: sai@nihs.go.jp

Funding information
This research was partially supported by the Research on Regulatory Science of Pharmaceuticals and Medical Devices grant (JP18mk0101052) from Japan Agency for Medical Research and Development (AMED). The funding source had no role in the design, conduct, analysis, or reporting of the study.

Abstract
Allopurinol-related severe cutaneous adverse reactions (SCARs) are strongly associated with HLA-B*58:01, the allele frequency (AF) of which is largely different among East Asians. However, evidence of population differences in SCAR development and relevance of genetic and/or other risk factors in the real-world remain unelucidated. This study aimed to evaluate population differences in allopurinol-related SCAR incidence related to genetic and/or other risk factors among East Asians in the real-world. A population-based cohort study was conducted using claims databases from Taiwan, Korea, and Japan. New users of allopurinol (311,846; 868,221; and 18,052 in Taiwan, Korea, and Japan, respectively) were followed up to 1 year. As control drugs, phenytoin and carbamazepine were used. The crude incidence rate ratios (IRRs) of SCARs for allopurinol against phenytoin or carbamazepine were the highest in Taiwan (IRR, 0.62 and 1.22; 95% confidence interval [CI], 0.54–0.72 and 1.01–1.47, respectively), followed by Korea (IRR, 0.34 and 0.82; 95% CI, 0.29–0.40 and 0.77–0.87), and the lowest in Japan (IRR, 0.04 and 0.16; 95% CI, 0.02–0.08 and 0.09–0.29). This order was accordant with that of AF ratios (AFRs) reported of HLA-B*58:01 against alleles responsible for phenytoin- or carbamazepine-related SCARs. The IRRs were higher in patients with chronic kidney disease, females, and elderly. This study demonstrated population differences in the risk of allopurinol-related SCAR development among East Asians based
INTRODUCTION

Ethnic or population differences in drug responses is a critical issue to consider in global drug development and postmarketing drug safety evaluation.1–3 The observed differences among populations or ethnicities reflect the overall intrinsic and extrinsic factors associated with ethnicity.4 Functional genetic polymorphisms are major intrinsic factors that may cause differences in drug response between ethnic groups. Knowledge of differences in allele frequencies (AFs) of functional genetic polymorphisms among different ethnic groups has been increasing, although the influence of genetic polymorphisms in real-world is not always considerable, or could be masked by other extrinsic factors.5 Leveraging the real-world data, including the ones from health insurance claims databases, has offered a key resource to promote efficient pharmacovigilance.6–8 Population-based claims databases have become available in drug safety research in East-Asian countries and collaborative research have been initiated.9–15 For facilitating appropriate planning of risk management strategy, it would be beneficial to demonstrate population differences in risk of adverse drug reactions (ADRs) and its dependency of functional genetic factors as well as other risk factors using real-world data. However, there have been very limited studies examining real-world evidence of population differences of ADRs.

Severe cutaneous adverse reactions (SCARs) to drugs, including Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS), are rare, but serious, potentially resulting in life-threatening, infectious, or chronic sequelae.16–20 Allopurinol, an antigout agent, is one of the most frequent causes of SCARs in Asia and Europe.21–24 Previous studies indicated that the allele human leukocyte antigen (HLA)-B*58:01 is a strong functional genetic factor for allopurinol-induced SCARs in various populations.25–36 The AFs of HLA-B*58:01 differed among populations of different ethnic origins1 (e.g., relatively high in Chinese [0.101] and Koreans [0.061], but rare in Japanese [0.004], and Europeans [from 0.005 to 0.012]; Table S1), thus, those differences between East Asians are more than 25-fold. The incidence of allopurinol-induced SCARs was demonstrated to be reduced by prospective screening of the HLA-B*58:01 allele in Chinese and Koreans.34–36 In contrast, although genetic polymorphisms associated with SCAR development by phenytoin (CYP2C9*3, HLA-B*13:01, HLA-B*15:02, and HLA-B*51:01)37,38 and carbamazepine (HLA-B*15:02, HLA-B*15:11, and HLA-A*31:01)33,38–41 have been identified, population differences in AFs of these genetic factors are very small among East Asians; less than twofold (Table S1).

In real-world scenarios, measuring ADR incidences can vary according to regionally different medical practices, including diagnostic criteria and coding rule as well as dosage, indication, and concomitant drugs. As for

Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THIS TOPIC?
Allopurinol-related severe cutaneous adverse reactions (SCARs) are strongly associated with HLA-B*58:01, the allele frequency of which is largely different among East Asians. However, there is no direct real-world evidence of population differences in SCAR development and the influence of genetic factors and/or other risk factors.

WHAT QUESTION DID THIS STUDY ADDRESS?
Do population differences in development of allopurinol-related SCARs, depending on genetic factors and/or other risk factors, exist among three East Asians in the real-world?

WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
The current analysis, based on comparisons of relative risks of SCAR incidence, provides real-world evidence of population differences in allopurinol-related SCAR development risk among East Asians, which was consistent with differences in reported HLA-B*58:01 frequencies, as well as identifying chronic kidney disease, female gender, and old age as common risk factors.

HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
This study helps to promote appropriate risk management strategies for allopurinol-related SCARs in the real-world considering risk factors based on the patients’ ethnicity. Our approach is useful for evaluating population differences in the real-world.
allopurinol-related SCARs, although ethnic differences in AF of HLA-B*58:01 have been recognized, evidence of population differences and the degree of influence of HLA-B*58:01 or other risk factors in the real-world have not yet been investigated.

In this study, we conducted a multilateral collaborative cohort study under a common protocol to evaluate population differences in the incidence of allopurinol-related SCARs and possible relevance of genetic factors as well as other risk factors among East Asians by using claims databases from Taiwan, Korea, and Japan. For this purpose, we established a common protocol applicable to three claims databases, with the aim of minimizing potential regional differences, such as diagnostic coding rules, and evaluated the influence of genetic factors using literature-based information, while also considering the effects of control drugs.

METHODS

Data sources

We used three population-based health insurance claims databases—the National Health Insurance Research Database (NHIRD) in Taiwan, the Health Insurance Review and Assessment Service (HIRA) database in South Korea, and the Japan Medical Data Center (JMDC) insurance claims database in Japan. The NHIRD and HIRA databases cover the entire population, including ~ 23 million and 50 million persons, respectively, and are established from national insurance claims. The JMDC database is commercially available and provides claims data for patients with employer-based insurance that covers around 3 million persons. These databases have been used for collaborative research in Asia and studies on SCARs.

Study design

We developed a common protocol and conducted retrospective cohort studies by using the claims databases in Taiwan (from January 2010 to December 2015), Korea (from January 2009 to December 2016), and Japan (from January 2005 to September 2016). Based on our focus to determine the impact of genetic factors on population differences in SCAR development, we selected allopurinol as a target drug and phenytoin or carbamazepine as a control drug, although the indication of these control drugs—epilepsy and other psychoneurotic conditions—were different from that of allopurinol. The differences in AFs of functional genetic factors of phenytoin or carbamazepine for SCAR development (< 2-fold compared with Japan) are little or considerably smaller than those of allopurinol (> 25-fold) among East Asians (see Table S1). By comparing with one of the negative control drugs regarding the AFs of functional genetic factors, we can eliminate the potential regional differences in the diagnostic criteria of SCARs and the way of coding among regions, although, basically, the diagnostic criteria of SCARs seem to be common in the three countries. A base cohort was composed of new users of allopurinol, carbamazepine, or phenytoin. The cohort entry date was defined as the date of the first prescription of the target drug or the control drug (index date). We excluded patients whose record durations were less than 12 months before the entry date and those who were diagnosed with any SCAR (SJS, TEN, DIHS, or DRESS) before the index date.

Study patients were followed from their first prescription of any of the study drugs (allopurinol, phenytoin, or carbamazepine) until when the following events first occurred: the first hospitalization with the diagnosis of SCAR (SJS, TEN, DIHS, or DRESS); discontinuation of the study drug (gap period: 30 days after the expected end date of any prescription) or switch to another study drug; concomitant use of a study drug, or phenobarbital or zonisamide (an anti-epilepsy drug for which AFs of functional genetic factor for SCARs are different among East Asians); death; the day after 1 year from the index date; or the last day of the data collection period in each dataset.

Outcomes

The primary outcome was the first hospitalization with the diagnosis of SCAR (SJS, TEN, DIHS, or DRESS), for which a study drug was suspected to be a cause. We identified the incidence of SCAR based on the International Classification of Diseases, 9th revision clinical modification (ICD-9 CM) codes (695.1x or 693.0) in Taiwan or the International Classification of Diseases, 10th revision (ICD-10) codes (L51.1, L51.2, L51.3, or L27.0) in Korea and Japan. SCAR cases were considered as the outcome if a study drug was not prescribed following discharge. The secondary outcomes were the components of SCARs: one was the composite of SJS and TEN, whereas the other was DIHS/DRESS.

Confounding factors

In order to compare the characteristics of patients among the three countries, and to take into account the potential confounders and/or effect modifiers, we collected the following information: age at cohort entry; gender; year of cohort entry; comorbidities at 1-year baseline period before the index date, including skin disorders, allergic disease, liver disease, kidney disease, and malignant lymphoma (see Table S2); and
recent and concurrent use (within 1 month before or after the index date) of the major drugs that cause SCARs (see Table 1).

Evaluation of population differences

Relative risk measures, including crude incidence rate ratios (IRRs) and adjusted hazard ratios (HRs) of SCARs were used for the evaluation of population differences to counterbalance the potential regional differences in the diagnostic criteria of SCARs and the way of coding among regions, assuming that diagnostic criteria and coding rules of a target ADR are common for all drugs within each region. For the evaluation of relevance to genetic factors, IRRs or HRs were compared with literature-based values of not only AFs but also AF ratios (AFRs) considering the potential impact of genetic polymorphisms associated with SCAR development by control drug, regarding the orders and magnitudes of differences. To investigate other nongenetic factors influencing the relative risk measures, we conducted secondary analyses stratified by patient characteristics.

Statistical analysis

We performed $\chi^2$ tests and one-way analysis of variance to compare the baseline characteristics among regions. There were no missing values. Crude incidence rates (IRs) in users of each study drug were calculated using the person-year method separately for each country with their 95% confidence intervals (CIs). In the primary analyses, the crude IRRs (allopurinol vs. phenytoin, and allopurinol vs. carbamazepine) of SCARs with their CIs were calculated separately for each country based on the Poisson distribution. We also estimated the HRs of SCARs and 95% CIs by using a Cox proportional hazard model. Multivariable Cox proportional hazard model, including all potential confounders/effect modifiers listed in Table 1, was used to estimate the fully adjusted HRs and 95% CIs (see Code S1, Dataset format S1).

We conducted two secondary analyses on crude IRs and crude IRRs: first, stratified by age group, sex, baseline comorbidities, and concomitant drug use at baseline period to evaluate the contributions of risk factors other than the functional genetic factors; and second, stratified by initial dosage of the study drug to determine its influence on the estimates of IRR. We conducted all analyses using SAS version 9.4 (SAS Institute).

The study protocol was approved by the ethics committee of the National Cheng Kung University, National Seoul University, Tokyo University of Science, and National Institute of Health Sciences.

RESULTS

Study populations and patient characteristics

From the three databases, 311,846, 868,221, and 18,052 eligible new users of allopurinol; 88,534, 28,154, and 487 eligible new users of phenytoin; and 74,692, 763,624, and 6627 eligible new users of carbamazepine were identified in Taiwan, Korea, and Japan, respectively. Patient characteristics varied among the three study populations for each study drug (Table 1). Although the proportion of men was the highest in Japan for allopurinol and carbamazepine users, it was the highest in Korea for phenytoin users. The mean age of the Japanese cohort was the lowest for any study drug users because the JMDC database covers only beneficiaries of health insurance for employees and their family members under 75 years of age. The median of initial dosage was the lowest in Japan for any study drug. The prevalence of some concomitant drugs was very different among the regions. For comorbidities at baseline, the Korean and Taiwanese cohorts had the highest prevalence of allergic disease and chronic kidney disease (CKD), respectively, in all study-drug cohorts. For the allopurinol cohorts, the prevalence of skin disease and liver disease were highest in Korea and Japan, respectively.

Incidence rates and relative risks of SCARs

The number of cases of the first hospitalization with the diagnosis of SCARs within 1-year follow-up after the start of each study drug prescription is shown in Table S3. The average follow-up time (years) in Taiwan, Korea, and Japan was 0.73, 0.98, and 0.47 for allopurinol cohorts; 0.73, 0.87, and 0.30 for phenytoin cohorts; and 0.85, 0.98, and 0.33 for carbamazepine cohorts, respectively. The crude IRs of SCARs per 1000 person-years for allopurinol users were the highest in Taiwan (IR, 2.57; 95% CI, 2.37–2.79), followed by Korea (IR, 2.31; 95% CI, 2.30–2.31), and the lowest in Japan (IR, 2.00; 95% CI, 1.24–3.21). Regarding IRs for phenytoin and carbamazepine, the IRs were the highest in Japan, followed by Korea, and the lowest in Taiwan (Table S3).

The crude IRRs of SCARs for allopurinol users compared with phenytoin or carbamazepine users were the highest in Taiwan (IRR, 0.62 and 1.22; 95% CIs, 0.54–0.72 and 1.01–1.47, respectively), followed by Korea (IRR, 0.34 and 0.82; 95% CI, 0.29–0.40 and 0.77–0.87), and the lowest in Japan (IRR, 0.04 and 0.16; 95% CI, 0.02–0.08 and 0.09–0.29; Figure 1). The same trends as the IRR order were observed for the adjusted HRs of SCARs for allopurinol users against phenytoin or carbamazepine users (HR, 1.24 and 1.26, 95% CI, 1.04–1.50 and 1.01–1.56, respectively, in Taiwan; HR, 0.60 and 0.67, 95% CI, 0.59–0.61 and 0.67–0.68, respectively, in Korea; and HR, 0.13 and 0.22, 95% CI, 0.03–0.54 and 0.10–0.50, respectively, in Japan; Figure 1). These trends


| Drug | Items | Taiwan | Korea | Japan | p value* |
|------|-------|--------|-------|-------|----------|
|     | Number of patients |       |       |       |          |
|     | Male | 237,985 | 76.3% | 731,006 | 84.2% | 16,987 | 94.1% | <0.001 |
|     | Female | 73,861 | 23.7% | 137,215 | 15.8% | 1065 | 5.9% |          |
|     | Mean (SD) | 56.88 | (16.8) | 53.85 | (16.2) | 47.5 | (11.4) | <0.001 |
|     | Median (IQR) | 57.0 | (25.0) | 54.0 | (24.0) | 48.0 | (16.0) | ND |
|     | Age group |       |       |       |          |
|     | 0–9 | 542 | 0.17% | 3324 | 0.38% | 87 | 0.5% | <0.001 |
|     | 10–19 | 3238 | 1.04% | 9412 | 1.08% | 159 | 0.9% |          |
|     | 20–29 | 13,983 | 4.48% | 45,345 | 5.22% | 829 | 4.6% |          |
|     | 30–39 | 35,978 | 11.54% | 116,75 | 13.43% | 2999 | 16.6% |          |
|     | 40–49 | 48,880 | 15.67% | 167,273 | 19.27% | 5866 | 32.5% |          |
|     | 50–59 | 68,308 | 21.90% | 203,284 | 23.41% | 5489 | 30.4% |          |
|     | 60–69 | 58,493 | 18.76% | 157,809 | 18.18% | 2289 | 12.7% |          |
|     | 70–79 | 51,260 | 16.44% | 122,924 | 14.16% | 334 | 1.9% |          |
|     | >80 | 31,164 | 9.99% | 42,275 | 4.87% | NA |          |          |
|     | Mean (SD) | 177.48 | (223.8) | 197.59 | (84.1) | 140 | (71.0) | <0.001 |
|     | Median (IQR) | 100 | (200.0) | 200 | (200.0) | 100 | (100.0) | ND |
|     | Drugs for acid-related disorders | 166,503 | 53.4% | 474,649 | 54.7% | 7857 | 43.5% | <0.001 |
|     | Diuretics | 64,852 | 20.8% | 135,531 | 15.6% | 1294 | 7.2% | <0.001 |
|     | Calcium channel blockers | 90,425 | 29.0% | 123,646 | 14.2% | 3717 | 20.6% | <0.001 |
|     | Corticosteroids for systemic use | 79,176 | 25.4% | 209,143 | 24.1% | 2341 | 13.0% | <0.001 |
|     | Antibacterials for systemic use | 90,619 | 29.1% | 234,110 | 27.0% | 4017 | 22.3% | <0.001 |
|     | Antimycobacterials | 3315 | 1.1% | 7891 | 0.9% | 59 | 0.3% | <0.001 |
|     | Immunosuppressants | 3145 | 1.0% | 8883 | 1.0% | 135 | 0.7% | 0.0012 |
|     | Anti-inflammatory and antirheumatic products | 221,435 | 71.0% | 466,485 | 53.7% | 7211 | 39.9% | <0.001 |
|     | Antigout preparations | 177,066 | 56.8% | 12,563 | 1.4% | 1575 | 8.7% | <0.001 |
|     | Anaesthetics | 3105 | 1.0% | 3856 | 0.4% | 2559 | 14.2% | <0.001 |
|     | Analgetics | 144,127 | 46.2% | 161,798 | 18.6% | 1778 | 9.8% | <0.001 |
|     | Antiepileptics | 16,582 | 5.3% | 29,988 | 3.5% | 353 | 2.0% | <0.001 |
|     | Cough and cold preparations | 102,594 | 32.9% | 114,804 | 13.2% | 2464 | 13.6% | <0.001 |
|     | Ophthalmological drugs | 51,301 | 16.5% | 10,470 | 1.2% | 1573 | 8.7% | <0.001 |
|     | Skin disease | 93,528 | 30.0% | 314,272 | 36.2% | 3594 | 19.9% | <0.001 |
|     | Allergic disease | 46,332 | 14.9% | 260,705 | 30.0% | 5091 | 28.2% | <0.001 |
|     | Liver disease | 46,935 | 15.1% | 139,397 | 16.1% | 6017 | 33.3% | <0.001 |
|     | Chronic kidney disease | 66,768 | 21.4% | 23,770 | 2.7% | 374 | 2.1% | <0.001 |
|     | Malignant lymphoma | 8425 | 2.7% | 83,180 | 9.58% | 796 | 4.4% | <0.001 |

(Continues)
### Table 1 (Continued)

| Drug Items | Taiwan | Korea | Japan | p value* |
|------------|--------|-------|-------|---------|
| **Phenytoin** | | | | <0.001 |
| Number of patients | 88,534 | 28,154 | 487 | |
| Oral alone/oral plus injection | 45,764/42,770 | 15,767/12,387 | 246/241 | |
| **Sex** | | | | |
| Male | 49,668 | 16,891 | 276 | 56.7% | <0.001 |
| Female | 36,866 | 11,263 | 211 | 43.3% | |
| **Age, years** | | | | |
| Mean (SD) | 60.13 (19.1) | 49.86 (29.4) | 41.2 | (17.2) | <0.001 |
| Median (IQR) | 61.0 (28.0) | 55 (35.0) | 43.0 | (27.0) | ND |
| **Age group** | | | | |
| 0–9 | 302 | 4065 | 15 | 3.1% | <0.001 |
| 10–19 | 1946 | 1268 | 50 | 10.3% | |
| 20–29 | 4228 | 1146 | 65 | 13.3% | |
| 30–39 | 6991 | 1689 | 80 | 16.4% | |
| 40–49 | 10,771 | 3272 | 100 | 20.5% | |
| 50–59 | 15,818 | 4737 | 97 | 19.9% | |
| 60–69 | 14,902 | 4413 | 66 | 13.6% | |
| 70–79 | 16,326 | 5080 | 14 | 2.9% | |
| >80 | 15,250 | 2484 | NA | |
| **Initial dosage; mg/day** | | | | <0.001 |
| Mean (SD) | 299.54 (712.4) | 345.77 (204.8) | 240 | (253.0) | |
| Median (IQR) | 300 (100.0) | 250 (100.0) | 200 | (50.0) | ND |
| **Concomitant drugs** | | | | <0.001 |
| Drugs for acid-related disorders | 62,117 | 1514 | 341 | 70.0% | |
| Diuretics | 26,214 | 504 | 82 | 16.8% | <0.001 |
| Calcium channel blockers | 34,306 | 336 | 152 | 31.2% | <0.001 |
| Corticosteroids for systemic use | 31,955 | 603 | 156 | 32.0% | <0.001 |
| Antibiotics for systemic use | 53,102 | 1474 | 291 | 59.8% | <0.001 |
| Antimycobacterials | 935 | 54 | 1 | 0.2% | <0.001 |
| Immunosuppressants | 959 | 100 | 5 | 1.0% | <0.001 |
| Anti-inflammatory and antirheumatic products | 50,341 | 662 | 249 | 51.1% | <0.001 |
| Antigout preparations | 6564 | 2163 | 6 | 1.2% | <0.001 |
| Anaesthetics | 8504 | 2 | 273 | 56.1% | <0.001 |
| Analgetics | 62,400 | 498 | 229 | 47.0% | <0.001 |
| Antiepileptics | 31,797 | 348 | 275 | 56.5% | <0.001 |
| Cough and cold preparations | 46,695 | 566 | 128 | 26.3% | <0.001 |
| Ophthalmological drugs | 22,144 | 216 | 111 | 22.8% | <0.001 |
| **Medical history** | | | | <0.001 |
| Skin disease | 27,056 | 9938 | 163 | 33.5% | |
| Allergic disease | 12,967 | 12,410 | 145 | 29.8% | <0.001 |
| Liver disease | 11,922 | 7585 | 110 | 22.6% | <0.001 |
| Chronic kidney disease | 13853 | 1205 | 3 | 0.6% | <0.001 |
| Malignant lymphoma | 783 | 1179 | 36 | 7.4% | <0.001 |

(Continues)
of relative risk measures among regions were in accordance with the order of the previously reported frequencies of the allele responsible for allopurinol-related SCARs—\textit{HLA-B*58:01}—0.101, 0.061, and 0.004, respectively (Table S1). The orders of IRRs and HRs also accorded with the AFRs of \textit{HLA-B*58:01} to alleles responsible for phenytoin-related SCARs or to those for carbamazepine-related SCARs (Table S1).

| Drug Items | Taiwan | Korea | Japan | p value* |
|------------|--------|-------|-------|----------|
| Carbamazepine | | | | |
| Number of patients | 74,692 | 763,624 | 6627 | |
| Sex | | | | |
| Male | 32,493 | 319,643 | 3356 | 50.6% | <0.001 |
| Female | 42,199 | 443,981 | 3271 | 49.4% | |
| Age; years | | | | |
| Mean (SD) | 57.24 | (16.8) | 54.92 | (16.5) | 35.0 | (19.5) | <0.001 |
| Median (IQR) | 58.0 | (23.0) | 56 | (24.0) | 38.0 | (32.0) | ND |
| Age group | | | | |
| 0–9 | 243 | 0.33% | 1617 | 0.21% | 1057 | 15.9% | <0.001 |
| 10–19 | 1341 | 1.80% | 15,994 | 2.09% | 683 | 10.3% | |
| 20–29 | 3240 | 4.34% | 44,226 | 5.79% | 606 | 9.1% | |
| 30–39 | 6461 | 8.65% | 79,224 | 10.37% | 1104 | 16.7% | |
| 40–49 | 11,094 | 14.85% | 126,656 | 16.59% | 1450 | 21.9% | |
| 50–59 | 17,439 | 23.35% | 181,698 | 23.79% | 1132 | 17.1% | |
| 60–69 | 15,470 | 20.71% | 151,001 | 20.02% | 468 | 7.1% | |
| 70–79 | 13,039 | 17.46% | 125,585 | 16.45% | 127 | 1.9% | |
| >80 | 6365 | 8.52% | 37,623 | 4.93% | NA | |
| Initial dosage; mg/day | | | | |
| Mean (SD) | 282.79 | (260.4) | 385.66 | (127.7) | 228 | (280.0) | <0.001 |
| Median (IQR) | 200 | (200.0) | 400 | (200.0) | 200 | (100.0) | ND |
| Concomitant drugs | | | | |
| Drugs for acid-related disorders | 43,359 | 58.1% | 15,433 | 2.02% | 2700 | 40.7% | <0.001 |
| Diuretics | 8323 | 11.1% | 5091 | 0.67% | 149 | 2.2% | <0.001 |
| Calcium channel blockers | 16,939 | 22.7% | 4244 | 0.56% | 463 | 7.0% | <0.001 |
| Corticosteroids for systemic use | 18,439 | 24.7% | 6384 | 0.84% | 1125 | 17.0% | <0.001 |
| Antibacterials for systemic use | 24,656 | 33.0% | 8006 | 1.05% | 2489 | 37.6% | <0.001 |
| Antimycobacterials | 220 | 0.3% | 327 | 0.04% | 1 | 0.0% | <0.001 |
| Immunosuppressants | 507 | 0.7% | 269 | 0.04% | 27 | 0.4% | <0.001 |
| Anti-inflammatory and antirheumatic products | 55,784 | 74.7% | 13,852 | 1.81% | 2459 | 37.1% | <0.001 |
| Antigout preparations | 4347 | 5.8% | 23,583 | 3.09% | 29 | 0.4% | <0.001 |
| Anaesthetics | 523 | 0.7% | 162 | 0.02% | 1040 | 15.7% | <0.001 |
| Analgetics | 46,533 | 62.3% | 6271 | 0.82% | 1864 | 28.1% | <0.001 |
| Antiepileptics | 16,675 | 22.3% | 3175 | 0.42% | 1936 | 29.2% | <0.001 |
| Cough and cold preparations | 28,342 | 37.9% | 4410 | 0.58% | 1967 | 29.7% | <0.001 |
| Ophthalmological drugs | 16,844 | 22.6% | 424 | 0.06% | 1056 | 15.9% | <0.001 |
| Medical history | | | | |
| Skin disease | 27,879 | 37.3% | 327,027 | 42.8% | 2512 | 37.9% | <0.001 |
| Allergic disease | 14,313 | 19.2% | 411,938 | 53.9% | 3180 | 48.0% | <0.001 |
| Liver disease | 9127 | 12.2% | 162,854 | 21.3% | 1472 | 22.2% | <0.001 |
| Chronic kidney disease | 6835 | 9.2% | 16,231 | 2.1% | 28 | 0.4% | <0.001 |
| Malignant lymphoma | 247 | 0.3% | 1432 | 0.2% | 129 | 1.9% | <0.001 |

SD, standard deviation; IQR, interquartile range; NA, not available; ND, not determined

*Regional difference was evaluated using chi-square test or one-way analysis of variance.
Secondary analyses

For secondary outcomes, the majority of cases were diagnosed as DIHS/DRESS in Korea and Japan for all the three study drugs, whereas the proportion of SJS/TEN against DIHS/DRESS cases was relatively higher in Taiwan than in the other two regions, especially for carbamazepine (Table S5). The crude IRs of SJS/TEN were the highest in Taiwan, followed by Korea, and the lowest in Japan in allopurinol and phenytoin users (Table S5). The crude IRRs of SJS/TEN were higher in Korea and Taiwan than in Japan when allopurinol was compared with either phenytoin or carbamazepine, and the IRRs of DIHS/DRESS were the highest in Taiwan, followed by Korea, and the lowest in Japan in both comparisons (Table S6).

The results of analyses stratified by possible effect modifier/confounder showed that in allopurinol users, the IRs as well as IRRs of SCARs were commonly higher in female patients and in patients with CKD in all the three populations (Table S4 and Figure 2). Furthermore, relatively higher IRs for allopurinol users and the IRRs in younger patients (<9-years-old) were observed in Taiwan and Korea, but no SCAR cases were found in Japan. In elderly patients (≥70-years-old), higher IRs and IRRs were commonly observed among all three populations (Table S4 and Figure 3). The order of IRRs (Taiwan > Korea > Japan) was almost similar to the results of primary analyses for any stratified groups. Although the IRs in users of allopurinol and concomitant drug(s) were higher than those of nonusers of concomitant drug(s) for acid-related disorders, diuretics/calcium channel blockers, antibacterials for systemic use/antimycobacterials, and anti-epileptic drugs, no apparent differences of IRRs were noted for any drug classes except for diuretics/calcium channel blockers. Among the three populations, the IRRs were the highest in Korea in concomitant drug users for many of the drug classes (data not shown).

The event rates and relative risks stratified by initial dosage of the study drug are shown in Tables S7 and S8. The IRs did not clearly differ by initial dosage except for phenytoin in Taiwan. Although the IRRs were lower in the higher dosage group except in Japan, the order was consistently the highest in Taiwan, followed by Korea, and the lowest in Japan in each stratified group.

DISCUSSION

Contribution of genetic factors and other risk factors to allopurinol-related SCARs

In the real-world, factors potentially influencing allopurinol-related SCARs include not only genetic polymorphisms but also other intrinsic and extrinsic factors, which could vary considerably across regions. To the best of our knowledge, this is the first study that demonstrated a population differences among East Asians in the incidence of
allopurinol-related SCARs in the setting of daily clinical practice by using claims databases. The trends in both of the crude IRRs and HRs of SCARs for allopurinol users compared with those of phenytoin or carbamazepine among three countries (Taiwan > Korea > Japan), with a considerably larger difference between Japan and the two other countries (Figure 1), were in accordance with the order of the AFR of HLA-B*58:01 to responsible alleles for SCARs by a control drug (allopurinol/phenytoin or allopurinol/carbamazepine; Table S1). These findings support our hypothesis that the differences in genetic factors could contribute to the integrated population differences in the risk of allopurinol-related SCAR development among the three East Asian populations. Clinical application of genetic testing of HLA-B*58:01 before allopurinol therapy was limited because this HLA test had not been covered by the National Health Insurance in all countries. We found that the implementation rate of HLA-B*15:02 testing for carbamazepine therapy, which was available for health insurance in Taiwan since June 2010, was also very low (5%). Thus, even a possible regional difference in disease recording might not influence our evaluation approach of population differences by using IRR.

This study indicated that CKD, being female, and elderly patients could be at risk for allopurinol-related SCARs in all three populations. Clinical application of genetic testing of HLA-B*58:01 before allopurinol therapy was limited because this HLA test had not been covered by the National Health Insurance in all countries. We found that the implementation rate of HLA-B*15:02 testing for carbamazepine therapy, which was available for health insurance in Taiwan since June 2010, was also very low (5%). Thus, the impact of genetic testing was negligible in this study (Table S1).

Although the proportion of SJS/TEN cases against that of DIHS/DRESS cases varied among regions (Table S5), the order of crude IRRs (Taiwan > Korea > Japan) was consistent for DIHS/DRESS. Because the diagnosis criteria adopted in each country originated from the same criteria, the higher proportion of SJS/TEN versus DIHS/DRESS in Taiwan (Table S5) might be attributed to the region-specific practice of disease recording. Because patients with SJS/TEN are usually treated in intensive care unit (ICU) in Taiwan, we repeated the primary analyses using a modified SCAR definition, including ICU treatment. The result revealed that IR values decreased, but the IRR (allopurinol/phenytoin [A/P]) and IRR (allopurinol/carbamazepine [A/C]) for SCARs obtained using the modified definition were similar to those obtained using the original definition (data not shown). Thus, even a possible regional difference in disease recording might not influence our evaluation approach of population differences by using IRR.

This study indicated that CKD, being female, and elderly patients could be at risk for allopurinol-related SCARs in all three populations. We found that CKD had much higher, smaller, and little impact on the IRs of SCARs by allopurinol, phenytoin, and carbamazepine, respectively. This finding is also consistent with those from studies showing that CKD is a risk factor for allopurinol-related SCARs.25,36 Because renal function is known to be lower in elderly and female individuals, these factors would be related. Notably, the order of IRRs (A/P and A/C) for the three populations in each stratified group (i.e., males, females, CKD presence, CKD absence, and each age group) was mostly constant (Taiwan > Korea > Japan; Figures 2, 3), and thus, this trend was consistent with the order of AFRs. This finding indicates that age, gender, and renal function together with HLA-B*58:01 may modulate the

**FIGURE 2** Comparison of incidence rate ratios of allopurinol-related SCARs among the three East Asian populations stratified by sex and chronic kidney disease. CI, confidence interval; IRR, incidence rate ratio; ND, not determined; SCARs, severe cutaneous adverse reactions.
incidence of allopurinol-related SCARs in addition to genetic factors.

Although the proportion of concomitant drug users for phenytoin and carbamazepine was lower in the Korean population and the IRRs of phenytoin- and carbamazepine-related SCARs were lower in the concomitant-drug user group in Korea (data not shown), the order of HRs (A/P and A/C) which adjusted for concomitant drugs among regions was consistent with that of crude IRRs. This finding suggests that regional difference in concomitant drug usage with antiepileptic agents might not have a significant impact on population differences of SCAR risk.

Although the initial dosages of the three study drugs were different among the regions, the order of IRRs among regions was constant for each stratified group (Table S8), in accordance with the order of AFRs (Table S1). Furthermore, IRRs of the higher dosage groups in Japan (for whole dosage or >median) were lower than those of the lower dosage groups of Taiwan and Korea. Thus, different initial dosages among countries may not affect the current evaluation results based on IRR comparison.

The Japanese cohort was younger than other two cohorts because patients older than 75 years were not included in the database; hence, we conducted an ad hoc analysis to determine the possible impact of the difference of age distribution among the three study populations. We estimated the age-adjusted (standardized) IRRs of SCARs for Korean and Taiwanese cohorts by applying age-group distribution of Japanese cohort as the standard population. Although the IRRs for Korean and Taiwanese cohorts were lower than those in the primary analysis, we confirmed that the trend of the IRRs (A/P and A/C) was the same as in the primary analysis (i.e., Taiwan > Korea > Japan; data not shown).

**Strengths and limitations of this study**

The primary strength of our study is the cohort design using population-based databases, including two national databases covering the entire population in Taiwan and South Korea, which ensures the generalizability of our results. Although the proportion of elderly patients was small in the Japanese database, the general population setting can reflect routine medical practice.

This study has several limitations. First, our SCAR definition based on claims has not been validated. However, we restricted the SCAR definition only to hospitalized cases with discontinuation of the study drug to reduce misclassification bias for relative risk measures. Second, regional differences might exist in the diagnosis or coding criteria (ICD-9 in Taiwan or ICD-10 codes in Korea and Japan). Third, information for other potential confounders/effect modifiers was not available in this study. To eliminate these limitations, we performed the analysis using relative risk measures (IRRs and HRs) against a reference drug and compared the order or degree of relative risks among populations to evaluate population differences in allopurinol-related SCAR development. This approach can also serve our primary purpose, to clarify the relevance of genetic factors.
Meaning of the study

Overall, this study has provided clinically and regulatory important suggestions. First, this study demonstrated real-world evidence of ethnic differences in allopurinol-related SCARs among East Asians, which are possibly related to ethnic differences in the responsible genetic factor, as well as other common risk factor. Furthermore, this finding would provide insights into the risk management strategy to minimize the incidence of SCAR. This might promote global drug development and/or international pharmacovigilance while taking into account risk populations with specific genetic polymorphisms and other common risk factors, as well as facilitate the development of domestic risk management strategy (i.e., selection of the right medication for individual patients in clinical practice by considering the risk factors based on their ethnicity). In addition, our approach based on a common protocol applicable to claims databases in different regions could facilitate research on other drugs to evaluate population differences and intrinsic and extrinsic factors in the real-world.

CONCLUSIONS

This study demonstrated the population differences in allopurinol-related SCAR development in East Asians in the real-world setting. The observed population differences were related to the differences in the reported AFs of responsible genetic polymorphisms, in addition to other common risk factors such as CKD, female gender, and advanced age. These findings provide important insights into appropriate risk management strategies while considering the risk factors based on the patients’ ethnicity. However, the size of population remains limited, especially for Japan, and thus further studies with larger population sample is warranted.

ACKNOWLEDGMENT

The authors wish to thank Dr. Takuya Imatoh, Division of Medicinal Safety Science, National Institute of Health Sciences, for his advisory comments on interpreting the results.

CONFLICT OF INTERESTS

Dr. Sato reports grants from AMED (JP18mk0101052) during the conduct of the study as well as grants from AbbVie GK; personal fees from Daiichi Sankyo Co., Ltd.; personal fees from Astellas Pharma Inc.; and personal fees from Nobelpharma Co., Ltd. outside the submitted work. Dr. Tohkin reports grants from AMED (JP18mk0101052) during the conduct of the study as well as grants from Daiichi Sankyo and from Towa Pharmaceutical Co., LTD., outside the submitted work. Mr. Fujita reports grants from AMED (JP18mk0101052) during the conduct of the study and personal fees from Daiichi Sankyo Co., Ltd., outside the submitted work. Drs. Kumagai, Saito, and Sai report grants from AMED (JP18mk0101052) during the conduct of the study. All other authors declared no competing interests for this work.

AUTHOR CONTRIBUTIONS

T.S. and K.S. wrote the manuscript. T.S., K.S., and Y.S. designed the research. T.S., C.C., H.P., Y.K., M.Y., M.F., Y.K., M.T., Y.S., and K.S. performed the research. T.S., C.C., H.P., and M.F. analyzed the data.

REFERENCES

1. Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet. 2012;27:9-54.
2. Huang SM, Temple R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther. 2008;84:287-294.
3. Oishi M, Hiro S, Matsuoka N, et al. A comparison of the pharmacokinetics and drug safety among East Asian populations. Ther InnovRegul Sci. 2014;48:393-403.
4. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Ethnic factors in the acceptability a foreign clinical data E5 (R1). https://database.ich.org/sites/default/files/E5_R1_Guideline.pdf. c1998. Accessed February 5, 1998.
5. Hasunuma T, Tohkin M, Kaniwa N, et al. Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians. Br J Clin Pharmacol. 2016;81:1078-1079.
6. Singh G, Schultzess D, Hughes N, Vannieuwenhuyse B, Kalra D. Real world big data for clinical research and drug development. Drug Discov Today. 2018;23:652-660.
7. Sultana J, Trotta F, Addis A, et al. Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy. Drug Saf. 2020;43:1-5.
8. Hsieh CY, Su CC, Shao SC, et al. Taiwan’s National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349-358.
9. Lai EC, Man KKC, Chaiyakunapruk N, et al. Databases in the Asia-Pacific Region: the potential for a distributed network approach. Epidemiology. 2015;26:815-820.
10. AsPEN collaborators, Andersen M, Bergman U, et al. The Asian Pharmacoepidemiology Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia. Pharmacoepidemiol Drug Saf. 2013;22:700-704.
11. Pratt N, Andersen M, Bergman U, et al. Multi-country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study. Pharmacoepidemiol Drug Saf. 2013;22:915-924.
12. Pratt N, Chan EW, Choi NK, et al. Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries. Pharmacoepidemiol Drug Saf. 2015;24:858-864.
13. Roughead EE, Chan EW, Choi NK, et al. Variation in association between thiázolidinediones and heart failure across ethnic groups: retrospective analysis of large healthcare claims databases in six countries. Drug Saf. 2015;38:823-831.
14. Roughead EE, Chan EW, Choi NK, et al. Proton pump inhibitors and risk of Clostridium difficile infection: a multi-country study using sequence symmetry analysis. Expert Opin Drug Saf. 2016;15:1589-1595.
15. Raman SR, Man KK, Bahmanyar S, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry. 2018;5:824-835.
16. Duong TA, Valelyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390:1996-2011.
17. Roujeau JC, Allanore L, Liss Y, Mockenhaupt M. Severe cutaneous adverse reactions to drugs (SCAR): definitions, diagnostic criteria, genetic predisposition. Dermatol Sinica. 2009;27:203-209.
18. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online. 2002;8:5.
19. Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2010;85:131-138.
20. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1607.
21. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25-32.
22. Ramasamy SN, Korb-Wells CS, Kannangara DR, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950–2012. Drug Saf. 2013;36:953-980.
23. Choudhry S, McLeod M, Torchia D, Romanelli P. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol. 2013;6:31-37.
24. Yang MS, Lee JY, Kim J, et al. Searching for the culprit drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis from a nationwide claim database in Korea. J Allergy Clin Immunol Pract. 2020;8:690-695. e2.
25. Hung SI, Chung W-H, Liou L-B, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;A:42:4134-4139.
26. Chiu ML, Hu M, Ng MH, et al. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol. 2012;167:44-49.
27. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19:704-709.
28. Kang HR, Jee YK, Kim Y-S, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011;21:303-307.
29. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9:1617-1622.
30. Goncalo M, Coutinho I, Teixeira V, et al. HLA-B*5801 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. Br J Dermatol. 2013;167:660-665.
31. Somkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N. Association of HLA-B*5801 allele and severe cutaneous adverse reactions with allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. J Dermatol. 2005;A.102:4134-4139.
32. Choudhry S, McLeod M, Torchia D, Romanelli P. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol. 2013;6:31-37.
33. Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions. J Dermatol. 2016;43:758-766.
34. Ko TM, Tsai CY, Chen SY, et al. Use of HLA-B*5801 genotyping to prevent allopurinol induced severe cutaneous adverse reactions. J Dermatol. 2013;40:60-69.
35. Tang Y, Jin F, Zhang J, et al. Allopurinol is a risk factor for Stevens-Johnson syndrome and toxic epidermal necrolysis in China. J Dermatol. 2015;42:652-659.
36. Park HW, Kim DK, Kim S-H, et al. Efficacy of the HLA-B*5801 screening test in preventing allopurinol-induced severe hypersensitivity. J Allergy Clin Immunol Pract. 2017;5:312-318.
37. Choudhry S, McLeod M, Torchia D, Romanelli P. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol. 2013;6:31-37.
38. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9:1617-1622.
39. Tohkin M, Kaniwa N, Saito Y, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics. 2013;13:60-69.
40. Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions. J Dermatol. 2016;43:758-766.
41. Ko TM, Tsai CY, Chen SY, et al. Use of HLA-B*5801 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ 2015;351:h4848.
42. Jung JW, Kim DK, Park HW, et al. An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing. Genet Med. 2015;17:807-814.
43. Park HW, Kim DK, Kim S-H, et al. Efficacy of the HLA-B*5801 screening test in preventing allopurinol-induced severe hypersensitivity. J Allergy Clin Immunol Pract. 2017;5:312-318.
cutaneous adverse reactions in patients with chronic renal insufficiency—a prospective study. *J Allergy Clin Immunol Pract*. 2019;7:1271-1276.

37. Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. *JAMA*. 2014;312:525-534.

38. Su SC, Chen CB, Chang WC, et al. HLA alleles and CYP2C9*3 as predictors of phenytoin hypersensitivity in East Asians. *Clin Pharmacol Ther*. 2019;105:476-485.

39. Chung WH, Hung SI, Hong HS. Medical genetics: a marker for Stevens-Johnson syndrome. *Nature*. 2004;428:486.

40. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. *N Engl J Med*. 2011;364:1126-1233.

41. Mushiroda T, Takahashi Y, Onuma T, et al. Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population. *JAMA Neurol*. 2018;75:842-849.

42. Yang MS, Lee JY, Kim J, et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using National Health Insurance Database in Korea. *PLoS One*. 2016;11:e0165933.

43. Aihara M, Kano Y, Fujita H, et al. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. *J Dermatol*. 2015;42:768-777.

44. Kano Y, Tohyana M, Aihara M, et al. Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: Survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR). *J Dermatol*. 2015;42:276-282.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

---

**How to cite this article:** Sato T, Cheng CL, Park HW, et al. Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study. *Clin Transl Sci*. 2021;14:1002–1014. [https://doi.org/10.1111/cts.12964](https://doi.org/10.1111/cts.12964)